Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Liverpool confirms Arne Slot as Jurgen Klopp's replacement
Jiangsu edge Guangzhou to snap 17
British troops may be tasked with delivering Gaza aid, BBC report says
'Constantly learning' Imanaga off to impressive start with the Chicago Cubs
Dubai plans to move its busy international airport to a $35 billion new facility within 10 years
Pakistan appoints Gary Kirsten and Jason Gillespie as cricket coaches
China's top legislature concludes standing committee session
Company wins court ruling to continue development of Michigan factory serving EV industry
Wartime sex slaves' children file lawsuit
A warrant for Netanyahu’s arrest was requested. But no decision was made about whether to issue it
Winter tourism promotion adds allure to travelling Tibet